<DOC>
	<DOCNO>NCT01583374</DOCNO>
	<brief_summary>Apremilast new , orally available , small molecule drug specifically inhibit phosphodiesterase 4 ( PDE4 ) , enzyme modulates inflammatory cytokine . This clinical study test whether apremilast improve sign symptom ankylose spondylitis .</brief_summary>
	<brief_title>Study Apremilast Treat Subjects With Active Ankylosing Spondylitis</brief_title>
	<detailed_description>Patients assign two different treatment base chance ( randomize ) placebo apremilast ( 20 30 mg tablet ) . The duration study approximately 5 year . The double blind period ( patient physician know whether placebo apremilast take ) 24 week . At Week 16 , subject either ≥ 20 % improvement ≥ 1 unit improvement baseline least two four SpondyloArthritis international Society ( ASAS ) domains enter `` early escape '' current treatment double-blinded manner . However , subject permit continue study . At Week 24 , subject may enter long-term extension phase additional 4.5 year ( 236 week ) . At `` second escape '' ( Week 24 ) , apremilast 20 mg BID treat subject transition receive double-blinded apremilast 30 mg BID ; apremilast 30 mg BID remain double-blinded apremilast 30 mg BID may continue improve long duration treatment . After Week 24 early portion long-term extension Week 52 , subject continue either double-blinded apremilast 20 mg BID 30 mg BID treatment . After subject complete Week 52 terminate early study 52-week data base lock , open-label apremilast 20 mg BID 30 mg BID treatment provide .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Documented diagnosis Definite Ankylosing Spondylitis [ ( AS ) ; arthritis spine ] Bath Ankylosing Spondylitis Disease Activity Index ( BASDAI ) ≥ 4 Total back pain ≥ 4 On stable dose AS medication ( lack medication ) prior randomization week 24 Prior treatment Tumor Necrosis Factor ( TNF ) blocker biologic treatment AS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>spondylitis</keyword>
	<keyword>spondyloarthritis</keyword>
	<keyword>Spondyloarthropathy</keyword>
	<keyword>Oral preparation</keyword>
</DOC>